Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Accured Expenses (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Change in Accured Expenses data on record, last reported at $2.2 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 199.23% year-over-year to $2.2 million; the TTM value through Sep 2025 reached $15.1 million, up 198.15%, while the annual FY2024 figure was $5.7 million, 145.26% up from the prior year.
  • Change in Accured Expenses reached $2.2 million in Q3 2025 per SGMO's latest filing, up from $892000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $14.6 million in Q4 2022 and bottomed at -$8.5 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $487105.3, with a median of -$591000.0 recorded in 2025.
  • The widest YoY moves for Change in Accured Expenses: up 834.74% in 2021, down 2291.59% in 2021.
  • A 5-year view of Change in Accured Expenses shows it stood at $5.1 million in 2021, then soared by 187.32% to $14.6 million in 2022, then tumbled by 158.38% to -$8.5 million in 2023, then skyrocketed by 248.03% to $12.6 million in 2024, then crashed by 82.69% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.2 million in Q3 2025, $892000.0 in Q2 2025, and -$591000.0 in Q1 2025.